RLMD Relmada Therapeutics, Inc.

NASDAQ

$4.17

Relmada Therapeutics, Inc. (RLMD) Earnings News

Earnings press releases, previews and reviews for Relmada Therapeutics, Inc. (RLMD), newest first. Our most recent is preview: Relmada's Q3 Report Is a Test of Whether NDV-01's Year-End IND Timeline Holds.

Wednesday November 4, 2026 6:24 PM ET

Relmada's Q3 Report Is a Test of Whether NDV-01's Year-End IND Timeline Holds

Earnings Whispers · Preview

Tuesday November 3, 2026 7:00 AM ET

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Thursday August 6, 2026 4:05 PM ET

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thursday July 16, 2026 7:05 AM ET

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Tuesday May 12, 2026 4:05 PM ET

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update